The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...
One ALS patient received TRE-515 under the FDA program last year, and early signs suggest the therapy may help stabilize ...
The new project combines clinical data with advanced analytics and artificial intelligence in an effort to create ...
ALS is life‑changing, but new treatments, specialized care, and innovative research are bringing real hope. See how advances at University of Utah Health are shaping the future of ALS care.
A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...
Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully ...
Every few months for the past three years, Jeff Vierstra has been receiving infusions in his spine that target and disable a ...
Brooke Eby, a writer, speaker, and social media creator who lives with ALS, has been named ALS Network's Advocate of the Year. Through her advocacy work, Eby has increased awareness and raised more ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results